Wang Yong-Wei, Liu Sian-De, Lin Guan-Ling, Huang Evelyn-Jou-Chen, Keller Joseph Jordan, Wang Li-Hsuan
School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei City, Taiwan.
Department of Pharmacy, National Taiwan University Cancer Center, Taipei City, Taiwan.
Clin Transl Sci. 2024 Oct;17(10):e70039. doi: 10.1111/cts.70039.
Higher serum cholesterol levels have been associated with an increased risk of dry eye disease (DED). The relationship between statin (HMG-CoA reductase inhibitor) use and DED in patients with hyperlipidemia remains unclear. To investigate the association between statin use and the risk of DED in patients with hyperlipidemia, we conducted a population-based retrospective cohort study utilizing data from Taiwan's Longitudinal Generation Tracking Database. Patients were categorized into statin users and nonusers, with a 5-year follow-up period. The study identified patients with newly diagnosed hyperlipidemia, excluding those with prior DED diagnoses. Matching and adjustments for covariates resulted in 41,931 individuals in each group. Patients receiving statin therapy were compared with those unexposed. Cumulative exposure doses were also evaluated to assess dose-response relationships. The primary outcome was the incidence of DED diagnosed during the follow-up period. Cox proportional hazards regression models estimated the risk of DED, and conditional logistic regression analyzed the dose-response effect of statin exposure. Among 41,931 matched pairs, statin users exhibited a slightly increased risk of developing DED compared with nonusers (adjusted hazard ratio, 1.06; 95% CI, 1.02-1.11; p < 0.01). However, no dose-response relationship was observed between statin exposure and DED risk. Statin use among patients with hyperlipidemia is associated with a marginally higher risk of DED. These findings underscore the importance of regular eye examinations in this patient population to facilitate early detection and management of DED.
较高的血清胆固醇水平与干眼病（DED）风险增加有关。他汀类药物（HMG-CoA还原酶抑制剂）的使用与高脂血症患者的干眼病之间的关系仍不清楚。为了研究他汀类药物的使用与高脂血症患者患干眼病风险之间的关联，我们利用台湾纵向世代追踪数据库的数据进行了一项基于人群的回顾性队列研究。患者被分为他汀类药物使用者和非使用者，随访期为5年。该研究纳入新诊断为高脂血症的患者，排除既往有干眼病诊断的患者。对协变量进行匹配和调整后，每组有41931人。将接受他汀类药物治疗的患者与未接受治疗的患者进行比较。还评估了累积暴露剂量以评估剂量反应关系。主要结局是随访期间诊断出的干眼病发病率。Cox比例风险回归模型估计干眼病风险，条件逻辑回归分析他汀类药物暴露的剂量反应效应。在41931对匹配组中，与非使用者相比，他汀类药物使用者患干眼病的风险略有增加（调整后的风险比为1.06；95%CI为1.02-1.11；p＜0.01）。然而，未观察到他汀类药物暴露与干眼病风险之间的剂量反应关系。高脂血症患者使用他汀类药物与患干眼病的风险略高有关。这些发现强调了对该患者群体进行定期眼部检查以促进干眼病早期检测和管理的重要性。
